Literature DB >> 20596307

Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8.

Saadiya Haque1, Robert van Kirk.   

Abstract

BACKGROUND: The relationship between Hodgkin's lymphoma (HL) and plasma cell-type Castleman's disease (PCD) has been well documented. There have been over 20 cases reported in the literature and nearly all of them were either diagnosed concurrently, or were initially diagnosed as PCD and upon review were found to have interfollicular HL. Human herpes virus type 8 (HHV-8) is present in about 40% of cases with PCD. It predisposes patients to a much higher risk of other malignancies, including Kaposi's sarcoma and non-Hodgkin's lymphoma. Cases linked to HHV-8 are associated with a different morphology than cases that are not linked to HHV-8. It has been proposed that patients with both HL and CD will have lymph nodes with HHV-8-negative morphology.
MATERIALS AND METHODS: We present a series of three cases in a retrospective study where patients had both HL and PCD. Surgical pathology reports, clinical histories, and H and E and various immunohistochemical stains on initial work-up were examined and subsequent immunohistochemical stains for HHV-8 were obtained from the Methodist Hospital.
RESULTS: Patient 1 was diagnosed with PCD and interfollicular HL in the same lymph node. Patient 2 was first diagnosed with classic HL and 2 years later returned with enlarged lymph nodes clinically suspected to be recurrent HL. Histology showed angiofollicular hyperplasia and interfollicular plasmacytosis without Reed-Sternberg cells and a diagnosis of PCD was rendered. Patient 3, a male in his third decade, was diagnosed with nodular sclerosing HL in the thymus, and concurrently PCD in the mediastinal lymph nodes. All three cases had architectural features consistent with an HHV-8-negative morphology. Immunohistochemical stains for HHV-8 were done retrospectively and were negative.
CONCLUSION: All three of our patients with both HL and CD had HHV-8-negative lymph node morphology and absence of HHV-8 by immunohistochemistry. These patients, therefore, are not at an increased risk for the development of subsequent malignancies, when compared to HHV-8-positive patients. Included in our series is one unique case where the diagnosis of HL preceded CD by 2 years.

Entities:  

Keywords:  Castleman's disease; HHV-8; Hodgkin's lymphoma; plasma cell variant of Castleman's disease

Year:  2009        PMID: 20596307      PMCID: PMC2885879          DOI: 10.4103/0971-5851.60052

Source DB:  PubMed          Journal:  Indian J Med Paediatr Oncol        ISSN: 0971-5851


INTRODUCTION

The concept of Castleman's disease (CD) (angiofollicular lymph node hyperplasia, “giant” lymph node hyperplasia, angiomatous lymphoid hamartoma) has been evolving since Castleman first described it in 1956.[1] This disease is now recognized to include a widely variable range of clinical presentations, histological findings, variable disease course, and ancillary study findings. Clinical presentations range from an incidental finding in the course of an unrelated health issue to multiple systemic symptoms and syndromes. The tumor can be localized and solitary or systemic and multicentric. Histologically, tissues may be classified as hyaline vascular type, plasma cell type, or mixed type. The disease course may range from an asymptomatic course to a progressive and fatal outcome. CD has been associated with multiple viruses. Plasma cell-type CD (PCD) is often associated with human immunodeficiency virus (HIV), especially when multicentric. Recent discoveries have led to a new way of classifying variants of PCD, based on the presence of human herpes virus type 8 (HHV-8). Cases linked to HHV-8 have a different histopathology, clinical course, and likelihood of developing lymphoma[2] when compared to HHV-8-negative cases. A relationship between Hodgkin's lymphoma (HL) and PCD has been well documented. There have been 29 cases reported in the literature and nearly all of them were either diagnosed concurrently, or were initially diagnosed as PCD and upon review were found to have interfollicular HL.[3-7] To our knowledge, the HHV-8 status of these types of cases has not been reported, with the exception of few case reports.[8] In the following study, we report three cases of patients with both HL and CD and classify them by HHV-8 status based on morphology and immunohistochemical studies.

MATERIALS AND METHODS

Three patients are included in this series. Cases 1 and 2 were obtained from the Metro Health Medical Center archives. Case 3 was obtained from the Medical College of Wisconsin. Surgical pathology reports and clinical histories were obtained from the hospital information systems. All cases initially had H and E and various immunohistochemical stains on initial work-up. Immunohistochemical stains for HHV-8 were done by Methodist Hospital (Houston, TX) retrospectively.

RESULTS

Case 1, a 62-year-old HIV-negative female, was diagnosed with PCD and interfollicular HL concurrently in the same mediastinal lymph node [Figure 1]. The node morphology showed intact follicles and distinct mantle zones.
Figure 1

Case 1. Reed-Sternberg cells in the interfollicular area surrounded by numerous plasma cells, H and E stain, ×40

Case 1. Reed-Sternberg cells in the interfollicular area surrounded by numerous plasma cells, H and E stain, ×40 Case 2 was a 67-year-old HIV-negative male who was first diagnosed with mixed cellularity HL in a cervical lymph node [Figure 2]. Following treatment with chemotherapy and 10 months of remission, the patient returned with enlarged axillary lymph nodes clinically suspected to be recurrent HL. Histology showed angiofollicular hyperplasia and interfollicular plasmacytosis without Reed-Sternberg cells and a diagnosis of PCD was rendered. The follicles were intact, without lysis or hemorrhage, and mantle zones were well delineated.
Figure 2

Case 2. Bilobed Reed-Sternberg cells found in an effaced lymph node, H and E stain, ×40

Case 2. Bilobed Reed-Sternberg cells found in an effaced lymph node, H and E stain, ×40 Case 3, a 27-year-old HIV-negative male, was diagnosed with nodular sclerosing HL in the thymus [Figure 3] and concurrently PCD in the mediastinal lymph nodes.
Figure 3

Case 3. Nodular lesions with several Reed-Sternberg cells, H and E stain, ×40

Case 3. Nodular lesions with several Reed-Sternberg cells, H and E stain, ×40 All three cases had architectural features consistent with an HHV-8-negative morphology. Immunohistochemical stains for HHV-8 were negative in all cases [Figure 4].
Figure 4

HHV-8 stain was negative for all three patients, HHV stain, ×20

HHV-8 stain was negative for all three patients, HHV stain, ×20

DISCUSSION

Our study validated that cases associated with both HL and CD typically demonstrate an HHV-8-negative lymph node morphology. HHV-8 is present in about 40% of cases with multicentric PCD and a minority of cases with localized PCD.[9] It predisposes patients to a much higher risk of other malignancies, including Kaposi's sarcoma and non-Hodgkin's lymphoma and is associated with a worse prognosis. HHV-8-positive cases are associated with a different morphology than HHV-8-negative cases.[2] HHV-8-negative cases have enlarged, active, hyperplastic follicular centers with mitoses, macrophages with nuclear debris, and increased follicular dendritic cells. There is usually a thin but distinct mantle zone. HHV-8-positive PCD cases have follicles that show severe hemorrhage and lysis with dissolution of the germinal center. The mantle zone-interfollicular area boundary is obliterated with the presence of indistinct, irregular mantle zones. Additionally, HHV-8-positive cases are more likely to have plasma cell atypia with immunoblasts and plasmablasts present in the mantle zones and more pronounced vascular proliferation in the interfollicular areas. There is also intranodal sinus dilatation which is absent in HHV-8-negative cases.[2] All three of the patients in our series had a morphology consistent with the HHV-8-negative type of PCD. The etiology of this apparently heterogenous group of diseases currently classified as CD is not well understood. Numerous authors have tried to implicate IL-6 (a cytokine normally produced in the germinal center that serves to induce B-cell differentiation) because it is seen with an increased expression in PCD and most patients respond to treatment with anti IL-6 antibodies.[10-12] This may help explain the HHV-8-associated changes because HHV-8 encodes an IL-6 homolog.[13] In CD with concurrent HHV-8 infection, there is a total increase in the systemic levels of IL-6, which causes the different morphologies seen in HHV-8-positive cases. It has been suggested that CD should be divided into primary and secondary, with secondary being associated with conditions that result in an IL-6-rich environment.[10-12] This would include HIV, autoimmune disorders, and plasma cell dyscrasias. It has also been shown that Reed-Sternberg cells and mononuclear-variant cells produce IL-6.[11]One report says of 19 cases with both HL and CD, that the diagnosis of Hodgkin's disease was delayed in 16 cases.[3] The Castleman-like changes induced by IL-6 can make it harder for the pathologist to recognize the diagnostic Reed-Sternberg cells, and consequently, the diagnosis of a very treatable disease may then be missed.[3-7] Our series included one case (case 1) of interfollicular HL that was diagnosed concurrently in a mediastinal lymph node. Another case (case 3) presented concurrently with nodular sclerosing HL in the thymus and PCD in a mediastinal node. The most unusual in our series was the case 2 who presented with mixed cellularity HL first, and then 16 months later (10 months postchemotherapy induced remission) returned with PCD. To our knowledge, this is the first case of its kind. Our three patients each had a different subtype of classical HL (interfollicular, nodular sclerosing, mixed cellularity). This is not unusual because previous reports in patients with both HL and PCD included all types of classical HL as well as nodular lymphocyte-predominant HL.

CONCLUSION

It has been proposed that patients with both HL and CD will most often have lymph nodes with an HHV-8-negative morphology,[2] but our series is the first report to verify this concept in multiple patients. Our series of three cases showed morphology with HHV-8-negative features and were negative for HHV-8 by immunohistochemical studies. Included is the first reported case of HL preceding the PCD changes.
  13 in total

1.  Plasma cell variant of Castleman's disease occurring concurrently with Hodgkin's disease in the neck.

Authors:  D K Frank; D Charney; A Kashani
Journal:  Head Neck       Date:  2001-02       Impact factor: 3.147

2.  Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

Authors:  S M Hsu; S S Xie; P L Hsu; J A Waldron
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

3.  Hodgkin's disease presenting with the histological features of Castleman's disease.

Authors:  P R Maheswaran; A D Ramsay; A J Norton; W R Roche
Journal:  Histopathology       Date:  1991-03       Impact factor: 5.087

4.  Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases.

Authors:  A Zarate-Osorno; L J Medeiros; A D Danon; R S Neiman
Journal:  Arch Pathol Lab Med       Date:  1994-03       Impact factor: 5.534

5.  Simultaneous occurrence of Epstein-Barr virus associated Hodgkin's disease and HHV-8 related multicentric Castleman's disease: a fortuitous event?

Authors:  E Caussinus; F Meggetto; G Delsol; P Brousset
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

6.  Human herpesvirus 8 encodes a homolog of interleukin-6.

Authors:  F Neipel; J C Albrecht; A Ensser; Y Q Huang; J J Li; A E Friedman-Kien; B Fleckenstein
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 7.  Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review.

Authors:  Claire Larroche; Patrice Cacoub; Jean Soulier; Eric Oksenhendler; Jean-Pierre Clauvel; Jean-Charles Piette; Martine Raphael
Journal:  Am J Hematol       Date:  2002-02       Impact factor: 10.047

8.  Interleukin-6 gene expression in Castleman's disease.

Authors:  M B Leger-Ravet; M Peuchmaur; O Devergne; J Audouin; M Raphael; J Van Damme; P Galanaud; J Diebold; D Emilie
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

Review 9.  Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease).

Authors:  F A Abdel-Reheim; W Koss; E S Rappaport; D A Arber
Journal:  Arch Pathol Lab Med       Date:  1996-01       Impact factor: 5.534

10.  Expression of interleukin-6 in Castleman's disease.

Authors:  S M Hsu; J A Waldron; S S Xie; B Barlogie
Journal:  Hum Pathol       Date:  1993-08       Impact factor: 3.466

View more
  5 in total

1.  Diagnostic issues in a case of hodgkin lymphoma with castleman like features.

Authors:  Suganya K Reddy; Jinkala Sree Rekha; Sajini Elizabeth Jacob; Debdatta Basu
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-04       Impact factor: 0.900

2.  IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case.

Authors:  Akihito Momoi; Masaru Kojima; Takeshi Sakai; Junya Ajiro; Noriatsu Isahai; Kouichi Nagai; Sadao Aoki
Journal:  Int J Hematol       Date:  2013-01-29       Impact factor: 2.490

3.  Co-Existence of Multicentric Castleman's Disease and Kaposi's Sarcoma.

Authors:  Reza Yaghoobi; Nader Pazyar; Sadigheh Tavakoli
Journal:  Indian J Dermatol       Date:  2015 May-Jun       Impact factor: 1.494

4.  Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy.

Authors:  Amina Mohtaram; Mohammed Afif; Tanae Sghiri; Amal Rami; Rachida Latib; Fouad Kettani; Meryam Ben Ameur El Youbi; Saber Boutayeb; Tayeb Kebdani; Noureddine Benjaafar; Imane Aaribi; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2013-12-05

5.  Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease.

Authors:  Feng Li; Xiaomei Zhang; Yanting Guo; Yuandong Zhu; Yicun Wu; Yun Ling
Journal:  Case Rep Hematol       Date:  2018-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.